Krystal Biotech Q3 Vyjuvek Gross Margin 94%; Sales Top $1.1B Since Launch
Share
Why It Matters
Krystal Biotech's new medicine Vyjuvek is making money very efficiently. When a company keeps this much profit, it shows customers really want the product.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.